Maxim Group analyst Jason Kolbert weighed in on NeoStem (NASDAQ: NBS) following data last night from the AHA meeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE